Welcome, Guest. Please login or register.
April 22, 2024, 03:09:26 am

Login with username, password and session length


Members
  • Total Members: 37648
  • Latest: Mag2803
Stats
  • Total Posts: 773249
  • Total Topics: 66344
  • Online Today: 156
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 141
Total: 143

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Dolutegravir resistance is rare, but some risk factors can up the odds  (Read 1873 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 22,371
  • Threads: @jim16309
    • Social Media: Threads
Interesting read, although not surprising results.*

Aidsmap in article in full: https://www.aidsmap.com/news/dec-2023/dolutegravir-resistance-rare-some-risk-factors-can-odds

In Short:

Quote
No drug is immune to resistance, but dolutegravir, one of the most widely used HIV drugs, has so far shown an excellent barrier to resistance. Nevertheless, a large study that analysed data from several countries found that resistance was more common in people who took dolutegravir monotherapy or dual therapy with lamivudine, or who had resistance to NRTIs (the backbone drugs usually combined with dolutegravir).

In clinical and real-world studies, treatment failure on dolutegravir-based regimens is seen usually in fewer than 5% of participants. Even in case of treatment failure, very few people develop resistance to the drug which is why it is said to have a high barrier to resistance.

Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on 599 people who had detectable viral load on dolutegravir-based therapy and had resistance testing.  (540 of the ‘participants’ were included in the analysis)

Fourteen per cent of all participants had at least one integrase inhibitor resistance mutation and 3% had more than one. It is important to note that the presence of a resistance mutation does not directly translate into treatment failure, hence some mutations may be present without affecting viral suppression.

Monotherapy
Of all risk factors, being on dolutegravir monotherapy rather than triple therapy had the strongest association with dolutegravir resistance. While it is not surprising that monotherapy contributed to increased resistance, it is certainly surprising that there were 18 people on monotherapy as none of the existing HIV treatment guidelines supports its use.

Dual therapy
Dolutegravir-based dual therapy was also associated with an increased risk of dolutegravir resistance; particularly dual therapies comprising dolutegravir plus lamivudine (available as Dovato). Other dolutegravir dual therapies had a weaker association with resistance.

Despite other data giving reassurance about the efficacy of dolutegravir-based dual therapies, these findings warn that dual therapy, particularly with lamivudine, may still come with some level of increased risk of resistance.

Loosli T. et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. The Lancet HIV 10: e733-e741, 2023.

DOI: https://doi.org/10.1016/S2352-3018(23)00228-X


*

DOLUMONO failed DTG monotherapy
https://forums.poz.com/index.php?topic=66233.0

MONCAY failed DTG monotherapy
https://forums.poz.com/index.php?topic=70588.msg

https://i-base.info/htb/31289

Swiss cohort - Monotherapy success (Primary infection)
https://forums.poz.com/index.php?topic=77185.msg


HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline leatherman

  • Global Moderator
  • Member
  • Posts: 8,623
  • Google and HIV meds are Your Friends
Re: Dolutegravir resistance is rare, but some risk factors can up the odds
« Reply #1 on: December 06, 2023, 06:48:22 am »
Quote
it is certainly surprising that there were 18 people on monotherapy as none of the existing HIV treatment guidelines supports its use.
monotherapy?!? Isn't that the very antithesis of what we know about HAART?

Without looking at the actual study, I notice this article doesn't even mention the biggest issue with resistance happening in the first place - non-compliance with daily treatment. That's not a fault of the drug; but of the patient. Neither is monotherapy is not the fault of the drug; but of the prescribing doctor.
leatherman (aka Michael)

We were standing all alone
You were leaning in to speak to me
Acting like a mover shaker
Dancing to Madonna then you kissed me
And I think about it all the time
- Darren Hayes, "Chained to You"

Online Jim Allen

  • Administrator
  • Member
  • Posts: 22,371
  • Threads: @jim16309
    • Social Media: Threads
Re: Dolutegravir resistance is rare, but some risk factors can up the odds
« Reply #2 on: December 06, 2023, 05:11:22 pm »
. Neither is monotherapy is not the fault of the drug; but of the prescribing doctor.

Yeah. Given the odds known of a shitty outcome down the line, it's concerning to see DTG monotherapy being prescribed.


« Last Edit: December 06, 2023, 05:30:23 pm by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.